Anastasia S. Mochalova

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Comparative analysis of the effectiveness of outpatient rehabilitation algorithms for patients with back pain

Comparative analysis of the effectiveness of outpatient rehabilitation algorithms for patients with back pain

Journal: Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury

Published: December 12, 2025

Role of training in biofeedback - an associated system of 3D video analysis of movements in comprehensive rehabilitation programs for patients after total knee arthroplasty

Role of training in biofeedback - an associated system of 3D video analysis of movements in comprehensive rehabilitation programs for patients after total knee arthroplasty

Journal: Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury

Published: December 12, 2025

Mutations in CREBBP and EP300 HAT and Bromo Domains Drive Hypermutation and Predict Survival in GI Cancers Treated with Immunotherapy.

Mutations in CREBBP and EP300 HAT and Bromo Domains Drive Hypermutation and Predict Survival in GI Cancers Treated with Immunotherapy.

Journal: Biomedicines

Published: September 10, 2025

Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].

Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 31, 2025

Maintenance avelumab in metastatic urothelial carcinoma: do tumour site and previous surgery matter?

Maintenance avelumab in metastatic urothelial carcinoma: do tumour site and previous surgery matter?

Journal: BJU international

Published: August 29, 2025

Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.

Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 15, 2025

Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real-World, Ambispective RAVE-Bladder Study.

Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real-World, Ambispective RAVE-Bladder Study.

Journal: Cancer medicine

Published: October 10, 2024

Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.

Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 23, 2024

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 29, 2024

Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications': [Annals of Oncology 34 (2023) p693-702].

Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications': [Annals of Oncology 34 (2023) p693-702].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 09, 2024

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.

Journal: Lancet (London, England)

Published: April 14, 2023

Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1.

Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1.

Journal: Bulletin of experimental biology and medicine

Published: February 03, 2023

Showing 1-12 of 21

Last Updated: 09/26/2026